Welcome to our dedicated page for Protagonist Therapeutics SEC filings (Ticker: PTGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Protagonist Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Protagonist Therapeutics's regulatory disclosures and financial reporting.
Protagonist Therapeutics, Inc. has a significant shareholder group led by Farallon Capital Management, L.L.C., which reports beneficial ownership of 6,433,119 Shares of common stock. This position represents 9.99% of the company’s outstanding common stock.
The Farallon-managed funds collectively hold 6,348,906 Shares plus 1,500,000 Common Stock Purchase Warrants. Due to a 9.99% Beneficial Ownership Limitation in the warrant terms, only 84,213 Shares underlying the Warrants are currently counted toward beneficial ownership, with the remaining 1,415,787 Warrants treated as not exercisable within 60 days.
Protagonist Therapeutics, Inc. President and CEO Dinesh V. Patel reported option exercises and share sales in August 2026 under a Rule 10b5-1 trading plan adopted on January 30, 2026. He exercised stock options for 100,000 shares of common stock at an exercise price of $21.58 per share and sold the resulting 100,000 shares in open-market transactions at weighted average prices of $149.11 on August 10 and $148.52 on August 11. The options exercised were fully vested and were scheduled to expire on October 11, 2026.
PTGX reports that an affiliate has filed to sell common stock under Rule 144. The planned sale covers 225,000 common shares, to be sold through J.P. Morgan Securities LLC on Nasdaq, with an aggregate market value of $33,583,500.
The filing lists 64,708,285 common shares outstanding. It also notes that 75,000 common shares were sold on 05/12/2026 for $7,508,850, and that the new shares are associated with an option exercise by the issuer, to be paid in cash.
State Street Corporation reported a passive ownership stake in Protagonist Therapeutics, Inc. common stock. It beneficially owns 3,321,554 shares, representing 5.2% of the outstanding common stock. State Street reports 0 shares with sole voting or dispositive power and 3,157,671 shares with shared voting power, while having 3,321,554 shares with shared dispositive power. Several investment management subsidiaries, including SSGA Funds Management, Inc. and State Street Global Advisors entities, are identified as the relevant investment advisers for these holdings.
Protagonist Therapeutics reported a sharp turnaround to profitability for the three and six months ended June 30, 2026, driven by collaboration economics. License and collaboration revenue reached $213.5 million in the quarter and $269.8 million year‑to‑date, largely from its Takeda rusfertide deal and a Janssen ICOTYDE milestone.
Net income was $162.8 million for the quarter and $166.6 million year‑to‑date, compared with losses in 2025, while cash, cash equivalents and marketable securities rose to about $849.5 million as of June 30, 2026. The Takeda opt‑out triggered a $200 million payment and positions Protagonist for royalties of 14–29% plus up to $775 million in sales milestones if rusfertide is approved and commercialized.
ICOTYDE received FDA approval in March 2026 for moderate‑to‑severe plaque psoriasis, earning a $50 million milestone and supporting future royalties of 6–10% and up to $580 million in additional milestones. Management expects research and development spending to increase significantly in the second half of 2026 as programs such as PN‑881, PN‑477, PN‑458 and PN‑8047 advance.
Protagonist Therapeutics reported a strong turnaround for the quarter ended June 30, 2026, driven by collaboration economics. License and collaboration revenue reached approximately $213.5 million, mainly from recognizing $192.4 million of a $200 million opt-out payment from Takeda and development services, plus earlier in 2026 a $50 million milestone from Johnson & Johnson tied to ICOTYDE’s FDA approval. Net income was about $162.8 million, compared with a loss a year earlier; diluted earnings per share were $2.29.
Cash, cash equivalents and marketable securities totaled roughly $849.5 million as of June 30, 2026, with stockholders’ equity of $841.5 million. ICOTYDE had its first full quarter of commercial sales, while rusfertide’s NDA for polycythemia vera is under FDA priority review with a PDUFA date in August 2026. The company highlighted a broad partnered and wholly owned pipeline, including the oral IL-17 antagonist PN-881 and triple agonist obesity candidate PN-477, and emphasized that expected milestones and tiered royalties of 6–10% on ICOTYDE and 14–29% on rusfertide are intended to fund ongoing R&D with no anticipated near-term equity financing.
Protagonist Therapeutics director William D. Waddill exercised stock options and sold the resulting shares in a pre-planned transaction. He exercised options for 9,000 shares of common stock at $16.54 per share and sold 9,000 shares at a weighted average price of $117.94 per share. The filing notes these trades were made under a Rule 10b5-1 trading plan adopted on February 27, 2026, indicating they were scheduled in advance. After the transactions, he directly owns 7,825 shares of common stock.
PTGX affiliate filed Form 144 reporting proposed and recent sales of Common Stock. The filing lists a proposed sale of 9,000 shares on 06/23/2026 described as an Exercise of Stock Options for cash. It also records 10b5-1 sales of 9,000 shares on 06/10/2026 for $969,152.40 and 9,000 shares on 05/29/2026 for $896,730.30.
Protagonist Therapeutics, Inc. held its 2026 annual stockholder meeting, with 64,305,185 common shares entitled to vote. Stockholders approved a new 2026 Equity Incentive Plan, which replaces the 2016 plan and allows future awards using remaining 2016 plan shares plus 650,000 new shares and certain returning shares.
Two Class I directors, Dinesh V. Patel and Lewis T. “Rusty” Williams, were re-elected to serve until the 2029 annual meeting. Stockholders also approved, on an advisory basis, executive compensation and ratified Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
Protagonist Therapeutics director William D. Waddill exercised stock options for 9,000 shares of common stock at strike prices of $16.54 and $11.80, then sold 9,000 shares in an open-market transaction at a weighted average price of $107.68 under a pre-arranged Rule 10b5-1 trading plan, leaving him with 7,825 shares held directly.